The FDA clearance that arrived on December 19, 2025 ended Cytokinetics’ 27-year run as a clinical-stage company without an approved product.
MYQORZO, the brand name for aficamten, a cardiac myosin inhibitor for adults with symptomatic obstructive hypertrophic cardiomyopathy, became available[1] by prescription in the United States on January 27, 2026. For a biotech founded in 1997 that had watched an ALS program fail and seen the FDA reject its heart failure drug in 2023, the launch was the company’s transition from pipeline-dependent speculation to commercial execution.
Armistice Capital, the global fund with concentrated holdings in healthcare and consumer sectors, holds a position in Cytokinetics (NASDAQ: CYTK). The fund does so alongside a broad roster of institutional holders: BlackRock, Fidelity, Vanguard, T. Rowe Price, Deep Track Capital, and others among approximately 449 institutions with reported positions who entered the stock tracking the company’s journey toward this commercial inflection point.
What MYQORZO Does and Who It Treats
MYQORZO is an allosteric, reversible inhibitor of cardiac myosin motor activity. It reduces ventricular contractility and lowers the left ventricular outflow tract gradient that characterizes obstructive HCM, a condition in which an abnormally thickened cardiac muscle impairs blood flow and limits exercise capacity. Cytokinetics estimates at least 100,000 patients in the United States are eligible for treatment.
The FDA approval rested on data from the SEQUOIA-HCM Phase 3 trial[2] , in which aficamten improved peak oxygen uptake by 1.8 milliliters per kilogram on average compared to no detectable improvement with placebo, the primary exercise capacity measure used to assess functional severity in this patient population.
MYQORZO requires a Risk Evaluation and Mitigation Strategy (REMS). Prescribers must obtain echocardiographic assessments of left ventricular ejection fraction before initiating treatment and at defined intervals during dose titration, because aficamten reduces LVEF and carries a boxed warning for heart failure risk. Initiation isn’t recommended for patients with LVEF below 55%. Within weeks of the January launch, more than 700 cardiologists had completed REMS registration and training.
A Differentiated REMS in a Two-Drug Market
MYQORZO enters a market Bristol Myers Squibb’s Camzyos has occupied alone since 2022. The BMS cardiac myosin inhibitor generated more than $1 billion[3] in combined U.S. and European sales in 2025.
Both drugs act on the same molecular mechanism; the practical competitive difference is their REMS protocols and prescribing requirements.
Camzyos carries a protocol mandating regular echocardiograms, drug-drug interaction screening, and dose interruption requirements that impose a real administrative burden on prescribers, patients, and pharmacies. MYQORZO’s label includes more flexible echocardiography timing during up-titration, no required drug-interaction monitoring, and dose adjustment rather than full interruption in most scenarios.
RBC Capital Markets analyst Leonid Timashev wrote[4] following the FDA decision that those distinctions should “materially lower barriers to prescribing” for MYQORZO relative to Camzyos.
Cytokinetics has set a commercial target of more than 50% new-to-brand prescription share among patients entering the cardiac myosin inhibitor class in 2026. More than 80% of the eligible oHCM population remains untreated with either drug, a patient base that both companies are only beginning to reach.
Launch Mechanics and the Access Ramp
Cytokinetics deployed more than 125 U.S. field sales colleagues at launch, concentrating early resources on approximately 750 high-volume “velocity” prescribers who account for roughly 80% of current CMI-class prescriptions. Broader commercial outreach extends to approximately 11,000 cardiologists across the country, most of whom haven’t written a prescription in the category.
At the 25th Annual Needham Virtual Healthcare Conference in April 2026[5] , Cytokinetics management described early prescribing activity among REMS-enrolled physicians as encouraging, with positive reimbursement outcomes for commercially insured patients. A bridge program supplies up to 12 months of free drug for commercially insured patients without active payer coverage and up to two months for Medicare patients awaiting formulary decisions.
Commercial insurance access comparable to Camzyos is projected by the fourth quarter of 2026. Payer coverage decisions, including plan-by-plan reviews and new-to-market blocks, typically lag launches for specialty drugs entering established categories.
Cytokinetics entered 2026 with approximately $1.2 billion in cash, providing a financial runway through the access-building period.
European Expansion and the ACACIA-HCM Data Readout
Cytokinetics is targeting Germany for a MYQORZO launch in the second quarter of 2026 under the AMNOG pricing framework, with additional Western European markets expected later in the year and a broader rollout across the region planned for 2027.
The European Commission had issued its marketing authorization approval in early 2026 following a positive recommendation from the EMA’s Committee for Medicinal Products for Human Use.
ACACIA-HCM, a pivotal Phase 3 trial testing aficamten in patients with symptomatic non-obstructive HCM, is expected to report data in that same second quarter.
Non-obstructive disease accounts for roughly half the total diagnosed and symptomatic hypertrophic cardiomyopathy population in the United States and has no approved treatment.
Bristol Myers Squibb’s attempt to expand Camzyos into the NHCM setting failed in Phase 3, which has kept institutional attention on Cytokinetics’ ACACIA-HCM data as one of the more closely watched specialty cardiology readouts of the year. A positive result would position Cytokinetics as the only company with an approved therapy for both forms of the disease.
Institutional Positioning
Cytokinetics enters its first full commercial year with roughly 449 institutional holders with reported positions, ranging from large passive index funds to active healthcare specialists. Armistice Capital holds its stake alongside that group. The company carries an approved drug in active U.S. distribution, a German launch targeted for the second quarter, and a Phase 3 readout in non-obstructive HCM due in the same window. Cytokinetics is no longer positioning for an approval. It’s managing the more complicated work of building a commercial business: formulary negotiations, prescriber education, payer timing, and a pipeline that could expand its addressable market before year-end.
[1]https://www.stocktitan.net/news/CYTK/cytokinetics-announces-myqorzotm-aficamten-now-available-in-the-u-s-vj216gmfzqrs.html
[2]https://www.ajmc.com/view/fda-approves-aficamten-for-obstructive-hypertrophic-cardiomyopathy
[3]https://www.thecerbatgem.com/2026/03/15/cytokinetics-teases-q2-phase-3-acacia-hcm-readout-as-myqorzo-launch-gains-traction-at-citi-conference.html
[4]https://www.biopharmadive.com/news/cytokinetics-myqorzo-fda-approval-obstructive-hypertrophic-cardiomyopathy-camzyos/808456/
[5]https://www.marketbeat.com/instant-alerts/cytokinetics-highlights-myqorzo-launch-progress-teases-2026-phase-3-readout-at-needham-conference-2026-04-13/